Nucleic Acid Amplification Testing Market Size, Share, Growth, Trends, and Global Industry Analysis: By Technique (Target amplification systems, Probe amplification systems, and Signal amplification), By Application (Infectious Diseases (Viruses, Bacteria, and Others), Cancer, Personalized Medicine, and Genetic and Mitochondrial Disorders), and Region Forecast 2020-2031

Nucleic Acid Amplification Testing Market size was valued at US$ 8.2 billion in 2024 and is expected to reach US$ 18.3 billion by 2031, growing at a significant CAGR of 12.2% from 2025-2031. One advantage of signal amplification systems is that they provide more options for target recognition sequences in some circumstances. The increased prevalence of infectious diseases, the rising need for better diagnostic measures, and rising investment in developing new biotechnological diagnostic procedures are driving the market.

Furthermore, nucleic acid amplification testing delivers the most exact detection. It is thus frequently preferred over older methods, owing to the growing need for improved testing methods and the biopharmaceutical industry's increased R&D expenditure.  However, the lack of skilled professionals and high costs hampers the market. For COVID-19 (SARS-CoV-2), a Nucleic Acid Amplification Test (NAAT) is a form of a viral diagnostic test. NAATs are genetic material detectors (nucleic acids). SARS-CoV-2 NAATs identify the RNA (ribonucleic acid) sequences that make up the virus's genetic material.

Moreover, rise in R&D for the development of advanced technologies for nucleic acid testing, an increase in demand for early-stage disease diagnosis and personalized medicine, rise in funding from public and private sectors for the healthcare infrastructure development, and surge in demand for nucleic acid testing from blood banks are anticipated to boost the market over the forecast timeframe. However, stringent regulatory guidelines, high cost and complexity in the testing, and lack of skilled professionals and sophisticated healthcare infrastructure in underdeveloped countries are hinder the growth of market in future years.

For instance, according to WHO 2018 data, approximately 9.6 Mn death occurred due to cancer around the globe. Moreover, rise in R&D for the development of advanced technologies for nucleic acid testing, increased in demand for early stage disease diagnosis and personalized medicine, raise in funding from public and private sectors for the healthcare infrastructure development, and surge in demand for nucleic acid testing from blood banks are anticipated to boost the market over the forecast timeframe. However, stringent regulatory guidelines, high cost and complexity in the testing, and lack of skilled professionals and sophisticated healthcare infrastructure in underdeveloped countries are hinder the growth of market in future years.

Key Developments:

• In January 2021, Xpert Xpress SARS-CoV-2 of Cepheid was launched for the qualitative detection of nucleic acid from the SARS-CoV-2 in upper respiratory specimens.